1. Home /
  2. Pharmaceuticals

Pharmaceuticals

Checking In on 2 Small Biotech Names That Had Big Quarters

Checking In on 2 Small Biotech Names That Had Big Quarters

Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.

Is Cannabis Legislation Closer Than You Think?

Is Cannabis Legislation Closer Than You Think?

Common sense should prevail when it comes to legislation, according to this cannabis executive.

An Example of How I Stalk a Trade

An Example of How I Stalk a Trade

With Aurinia Pharmaceuticals, the key is to be patient and to buy incrementally.

Nektar Therapeutics Sinks on Cancer Treatment Manufacturing Issues

Nektar Therapeutics Sinks on Cancer Treatment Manufacturing Issues

Nektar says there have been manufacturing issues in two batches of experimental cancer drugs.

The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

Let's see how the charts of GWPH are shaping up.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

NovoCure Looks Due for a Technical Correction

NovoCure Looks Due for a Technical Correction

Let's look at the charts and indicators in addition to following the fundamentals.

GW Pharma Surges on Marijuana-Based Epilepsy Drug Sales, Analyst Upgrades

GW Pharma Surges on Marijuana-Based Epilepsy Drug Sales, Analyst Upgrades

Shares of GW Pharmaceuticals surge following soaring sales of its marijuana-derived epilepsy drug that prompts two analysts to raise their stock-price targets.

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.

McKesson, Cardinal Health, AmerisourceBergen Propose Opioid Settlement: Report

McKesson, Cardinal Health, AmerisourceBergen Propose Opioid Settlement: Report

Three pharma distributors propose a $10 billion plan to a group of state attorneys general in opioid-abuse settlement.